Huong Thai Kemprowski, MD
Allergy & Immunology · Leesburg, VANPI 1679507719
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 24.5% of the total. 2025 is the largest year on record at $1,634, 2.3 times the $695 reported in 2019.
Across 351 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$952
- Pfizer$568
- Sanofi$539
- Amgen$376
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,98697%
- Education$2713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 86 | $2,020 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,226 |
| GSK | 57 | $952 |
| Pfizer | 31 | $568 |
| Sanofi | 17 | $539 |
| Amgen(2 entities) | 11 | $376 |
| Genentech USA, Inc. | 13 | $334 |
| Kaleo, Inc. | 13 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $295 |
| Novartis | 11 | $276 |
| Sanofi-aventis U.S. LLC | 3 | $239 |
| CSL Behring | 8 | $208 |
| Boehringer Ingelheim | 9 | $157 |
| Alk-abello, Inc | 2 | $138 |
| Biocryst US Sales Co., LLC | 3 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $90 |
| Optinose US, Inc. | 4 | $71 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| LEO Pharma Inc. | 2 | $46 |
| Galderma Laboratories, L.p. | 2 | $33 |
| AbbVie | 1 | $27 |
| Incyte Corporation | 1 | $25 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Organon | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,257 in reported general payments places this provider in the 70th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 35 | $1,800 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $489 |
| Montelukast Sodium | 14 | $73 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Leesburg
- Behnam DaghighLeesburg$99K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Andrew KimFredericksburg$104K
- Ananth ThyagarajanBurke$97K
- Larry BorishCharlottesville$92K
- Oral AlpanSpringfield$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.